William Blair Reiterates Outperform Rating for Janux Therapeutics (NASDAQ:JANX)

William Blair reissued their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX) in a research note published on Thursday,RTT News reports. William Blair also issued estimates for Janux Therapeutics’ Q4 2024 earnings at ($0.35) EPS, FY2024 earnings at ($1.28) EPS, Q1 2025 earnings at ($0.35) EPS, Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.37) EPS, FY2025 earnings at ($1.45) EPS, FY2026 earnings at ($1.74) EPS and FY2027 earnings at ($2.84) EPS.

A number of other equities analysts have also commented on JANX. UBS Group began coverage on shares of Janux Therapeutics in a research report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target on the stock. Wedbush reaffirmed an “outperform” rating and issued a $74.00 target price on shares of Janux Therapeutics in a research note on Thursday, August 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a research note on Thursday, November 7th. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $70.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a report on Thursday, November 7th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Janux Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $66.44.

Janux Therapeutics Stock Performance

NASDAQ:JANX opened at $48.76 on Thursday. The firm’s 50-day moving average is $49.76 and its 200-day moving average is $46.38. Janux Therapeutics has a 52-week low of $7.79 and a 52-week high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). The business had revenue of $0.44 million during the quarter, compared to the consensus estimate of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics’s quarterly revenue was down 82.6% compared to the same quarter last year. Sell-side analysts forecast that Janux Therapeutics will post -1.34 earnings per share for the current year.

Insider Buying and Selling at Janux Therapeutics

In related news, CEO David Alan Campbell sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $53.54, for a total transaction of $1,338,500.00. Following the transaction, the chief executive officer now directly owns 282,054 shares of the company’s stock, valued at approximately $15,101,171.16. This trade represents a 8.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Hollman Meyer sold 50,000 shares of the firm’s stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the transaction, the insider now directly owns 67,592 shares in the company, valued at approximately $3,106,528.32. This represents a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 420,610 shares of company stock worth $19,288,666 over the last quarter. 29.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Janux Therapeutics

Several hedge funds have recently bought and sold shares of JANX. ProShare Advisors LLC bought a new position in Janux Therapeutics in the 1st quarter valued at about $251,000. Lord Abbett & CO. LLC bought a new position in Janux Therapeutics in the 1st quarter valued at about $20,420,000. Vanguard Group Inc. increased its holdings in Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after buying an additional 378,477 shares during the period. StemPoint Capital LP bought a new position in Janux Therapeutics in the 1st quarter valued at about $4,580,000. Finally, Altitude Crest Partners Inc. bought a new position in Janux Therapeutics in the 1st quarter valued at about $7,278,000. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.